Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Metro Bank on track for FY after 'significant' increase in Q1 underlying profit

(Sharecast News) - Metro Bank said on Thursday that it remains confident of meeting full-year guidance as it reported a "significant" increase in first-quarter underlying profit versus the second half of 2024. In a first-quarter trading update, the bank put the jump in profit down to structurally higher net interest margin, driven by continued asset rotation and deposit optimisation.

Total net loans as at the end of March were £8.5bn, down 6% from the end of December last year. Metro said this reflects the £584m sale of its personal loan portfolio.

Customer deposits fell 4% to £13.8bn, driven by maturities of higher cost fixed-term deposits and continued focus on reducing excess liquidity and cost of deposits.

Chief executive Daniel Frumkin said: "During the first quarter of 2025, we have continued to deliver the strategic repositioning of Metro Bank's business, maintaining strong cost control while driving higher net interest margin by changing the mix of assets and remaining disciplined about deposits.

"We have seen further growth in our corporate and commercial lending, with Metro Bank's relationship banking and breadth of services creating differentiation for us in the market.

"Looking ahead, we will continue to play an important role in supporting our customers as the UK focuses on delivering economic growth. We remain firmly on track to meet our guidance given at full year."

At 0950 BST, the shares were up 3.3% at 107.60p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.